Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized single-blind active-controlled trial of CXG87 inhalation powder in adults with asthma
CTR20250298Phase 3Completed
- Sponsor
- Chance Pharmaceuticals
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of budesonide + formoterol in asthma, sponsored by Chance Pharmaceuticals. Started Jan 2025; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20250298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250298.